?-Linolenic Acid ethyl ester-d5

Confirm delete?

?-Linolenic Acid ethyl ester-d₅

Zoom

Cat No: 28185

Biochemicals - Isotopically Labeled Standards

α-Linolenic acid ethyl ester-d5 is intended for use as an internal standard for the quantification of α-linolenic acid ethyl ester (Item No. 10008199) by GC- or LC-MS. α-Linolenic acid ethyl ester is an esterified form of α-linolenic acid (Item Nos. 9...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

9Z,12Z,15Z-octadecatrienoic-17,17,18,18,18-d5 acid, ethyl ester

Correlated keywords:

?linolenic Cdk 2 LA EE ALA Streptococcus Candida Porphyromonas bio-diesel deuterated deuterium GCMS LCMS anti-oxidant

Product Overview:
α-Linolenic acid ethyl ester-d5 is intended for use as an internal standard for the quantification of α-linolenic acid ethyl ester (Item No. 10008199) by GC- or LC-MS. α-Linolenic acid ethyl ester is an esterified form of α-linolenic acid (Item Nos. 90210
21910). It increases cyclin E levels and the activity of Cdk2/cyclin E, ERK, and JNK in hepatic stellate cells when used at a concentration of 50 μM.{14161} α-Linolenic acid ethyl ester (25 μg/ml) inhibits the growth of S. mutans, C. albicans, and P. gingivalis by 98, 72, and 92%, respectively, in vitro.{47493} It has been found in biodiesel produced from castor oil using ethanol.{47494} α-Linolenic acid ethyl ester has been used as a substrate in lipid peroxidation assays for antioxidant activity.{47495}

Size	250 µg
Shipping	dry ice
CAS Number	203633-16-3
Molecular Formula	C₂₀H₂₉D₅O₂
SMILES	[2H]C([2H])([2H])C([2H])([2H])/C=C\C/C=C\C/C=C\CCCCCCCC(OCC)=O
Molecular Weight	311,5
Formulation	A solution in ethanol
Purity	≥99% deuterated forms (d1-d5)
Custom Code	3822.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.